Abstract
Objective The aim of this study is to identify the most appropriate threshold for Disruptive Mood Dysregulation Disorder (DMDD) diagnosis and the impact of potential changes in diagnostic rules on prevalence levels in the community.
Methods Trained psychologists evaluated 3,562 adolescents from the 2004 Pelotas Birth Cohort with the Development and Well-Being Behavior Assessment (DAWBA). The clinical threshold was assessed in three stages: symptomatic, syndromic and clinical operationalization. The symptomatic threshold identified the response category in each DAWBA item which separates normative misbehavior from a clinical indicator. The syndromic threshold identified the number of irritable mood and outbursts needed to capture children with high symptom levels. Clinical operationalization compared the impact of AND/OR rules for combining irritable mood and outbursts on impairment and levels of psychopathology.
Results At the symptomatic threshold, most irritable mood items were normative in their lowest response categories and clinically significant in their highest response categories. For outbursts some indicated a symptom even when present at only a mild level, while others did not indicate symptoms at any level. At the syndromic level, a combination of 2 out of 7 irritable mood and 3 out of 8 outburst indicators accurately captured a cluster of individuals with high level of symptoms. Analysis combining irritable mood and outbursts delineated non-overlapping aspects of DMDD, providing support for the OR rule in clinical operationalization. The best DMDD criteria resulted in a prevalence of 4%.
Conclusions Results provide information for initiatives aiming to provide data-driven and clinically-oriented operationalized criteria for DMDD.
Competing Interest Statement
Dr Laporte, Matijasevich, Munhoz, Santos, Barros, Pine, Leibenluft and Salum report no biomedical financial interests or potential conflicts of interest. Dr. Laporte, Matijasevich, Santos, Barros, Rohde and Salum are supported by the CNPq. Dr. Luis Augusto Rohde was on the speakers' bureau/advisory board and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Medice and Shire in the last three years. He receives authorship royalties from Oxford Press and ArtMed. He also received travel award for taking part of 2017 WFADHD, and 2018 APA meetings respectively from Novartis and Shire. The ADHD Disorder Outpatient Program chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Janssen-Cilag, Novartis, and Shire.
Funding Statement
The authors thank the children and families for their participation, which made this research possible. We also would like to thank the research team from the Pelotas 2004 Birth Cohort. The Pelotas 2004 Birth Cohort is conducted by the Graduate Program in Epidemiology of Universidade Federal de Pelotas, supported by Associaçã Brasileira de Saúde Coletiva (ABRASCO – Brazilian Association of Public Health). From 2009 to 2013, the 2004 birth cohort was funded by the Wellcome Trust (United Kingdom). Previous phases of the study were funded by the World Health Organization, Programa de Apoio a Núleos de Excelência (PRONEX – Support Program for Excellence Centers), Conselho Nacional de Desenvolvimento Cientí–fico e Tecnológico (CNPq – National Council for Scientific and Technological Development), the Brazilian Ministry of Health, and Pastoral da Criança (Child’s Pastoral).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosures Dr Laporte, Matijasevich, Munhoz, Santos, Barros, Pine, Leibenluft and Salum report no biomedical financial interests or potential conflicts of interest. Dr. Laporte, Matijasevich, Santos, Barros, Rohde and Salum are supported by the CNPq. Dr. Luis Augusto Rohde was on the speakers’ bureau/advisory board and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Medice and Shire in the last three years. He receives authorship royalties from Oxford Press and ArtMed. He also received travel award for taking part of 2017 WFADHD, and 2018 APA meetings respectively from Novartis and Shire. The ADHD Disorder Outpatient Program chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Janssen-Cilag, Novartis, and Shire.
Data Availability
Available upon request to the Pelotas Graduate Program.
